nodes	percent_of_prediction	percent_of_DWPC	metapath
Naltrexone—UGT1A1—Mycophenolic acid—systemic scleroderma	0.34	0.469	CbGbCtD
Naltrexone—UGT1A1—Mycophenolate mofetil—systemic scleroderma	0.19	0.262	CbGbCtD
Naltrexone—ABCB1—Lisinopril—systemic scleroderma	0.064	0.0882	CbGbCtD
Naltrexone—ABCB1—Captopril—systemic scleroderma	0.0479	0.066	CbGbCtD
Naltrexone—ABCB1—Mycophenolate mofetil—systemic scleroderma	0.0377	0.052	CbGbCtD
Naltrexone—ABCB1—Prednisone—systemic scleroderma	0.0301	0.0416	CbGbCtD
Naltrexone—ABCB1—Methotrexate—systemic scleroderma	0.0151	0.0209	CbGbCtD
Naltrexone—Tachycardia—Lisinopril—systemic scleroderma	0.000204	0.000744	CcSEcCtD
Naltrexone—Abdominal pain—Azathioprine—systemic scleroderma	0.000204	0.000743	CcSEcCtD
Naltrexone—Body temperature increased—Azathioprine—systemic scleroderma	0.000204	0.000743	CcSEcCtD
Naltrexone—Skin disorder—Lisinopril—systemic scleroderma	0.000203	0.00074	CcSEcCtD
Naltrexone—Malaise—Mycophenolate mofetil—systemic scleroderma	0.000203	0.000738	CcSEcCtD
Naltrexone—Hyperhidrosis—Lisinopril—systemic scleroderma	0.000202	0.000737	CcSEcCtD
Naltrexone—Diarrhoea—Captopril—systemic scleroderma	0.000202	0.000736	CcSEcCtD
Naltrexone—Decreased appetite—Mycophenolic acid—systemic scleroderma	0.000202	0.000736	CcSEcCtD
Naltrexone—Irritability—Methotrexate—systemic scleroderma	0.000202	0.000735	CcSEcCtD
Naltrexone—Syncope—Mycophenolate mofetil—systemic scleroderma	0.000202	0.000734	CcSEcCtD
Naltrexone—Feeling abnormal—Leflunomide—systemic scleroderma	0.000201	0.000731	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Mycophenolic acid—systemic scleroderma	0.000201	0.000731	CcSEcCtD
Naltrexone—Fatigue—Mycophenolic acid—systemic scleroderma	0.0002	0.00073	CcSEcCtD
Naltrexone—Nausea—Mometasone—systemic scleroderma	0.0002	0.000728	CcSEcCtD
Naltrexone—Anorexia—Lisinopril—systemic scleroderma	0.0002	0.000727	CcSEcCtD
Naltrexone—Gastrointestinal pain—Leflunomide—systemic scleroderma	0.000199	0.000725	CcSEcCtD
Naltrexone—Weight increased—Prednisone—systemic scleroderma	0.000199	0.000724	CcSEcCtD
Naltrexone—Constipation—Mycophenolic acid—systemic scleroderma	0.000199	0.000724	CcSEcCtD
Naltrexone—Pain—Mycophenolic acid—systemic scleroderma	0.000199	0.000724	CcSEcCtD
Naltrexone—Palpitations—Mycophenolate mofetil—systemic scleroderma	0.000199	0.000723	CcSEcCtD
Naltrexone—Weight decreased—Prednisone—systemic scleroderma	0.000198	0.00072	CcSEcCtD
Naltrexone—Loss of consciousness—Mycophenolate mofetil—systemic scleroderma	0.000198	0.000719	CcSEcCtD
Naltrexone—Cough—Mycophenolate mofetil—systemic scleroderma	0.000196	0.000714	CcSEcCtD
Naltrexone—Dizziness—Captopril—systemic scleroderma	0.000195	0.000712	CcSEcCtD
Naltrexone—Convulsion—Mycophenolate mofetil—systemic scleroderma	0.000195	0.000709	CcSEcCtD
Naltrexone—Depression—Prednisone—systemic scleroderma	0.000194	0.000708	CcSEcCtD
Naltrexone—Hypertension—Mycophenolate mofetil—systemic scleroderma	0.000194	0.000706	CcSEcCtD
Naltrexone—Urticaria—Leflunomide—systemic scleroderma	0.000194	0.000705	CcSEcCtD
Naltrexone—Abdominal pain—Leflunomide—systemic scleroderma	0.000193	0.000701	CcSEcCtD
Naltrexone—Body temperature increased—Leflunomide—systemic scleroderma	0.000193	0.000701	CcSEcCtD
Naltrexone—Acute coronary syndrome—Prednisone—systemic scleroderma	0.000192	0.0007	CcSEcCtD
Naltrexone—Feeling abnormal—Mycophenolic acid—systemic scleroderma	0.000191	0.000697	CcSEcCtD
Naltrexone—Chest pain—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000697	CcSEcCtD
Naltrexone—Myalgia—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000697	CcSEcCtD
Naltrexone—Arthralgia—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000697	CcSEcCtD
Naltrexone—Myocardial infarction—Prednisone—systemic scleroderma	0.000191	0.000696	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Lisinopril—systemic scleroderma	0.000191	0.000694	CcSEcCtD
Naltrexone—Anxiety—Mycophenolate mofetil—systemic scleroderma	0.000191	0.000694	CcSEcCtD
Naltrexone—Hypersensitivity—Azathioprine—systemic scleroderma	0.00019	0.000692	CcSEcCtD
Naltrexone—Gastrointestinal pain—Mycophenolic acid—systemic scleroderma	0.00019	0.000692	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Mycophenolate mofetil—systemic scleroderma	0.00019	0.000692	CcSEcCtD
Naltrexone—Insomnia—Lisinopril—systemic scleroderma	0.000189	0.000689	CcSEcCtD
Naltrexone—Discomfort—Mycophenolate mofetil—systemic scleroderma	0.000189	0.000688	CcSEcCtD
Naltrexone—Paraesthesia—Lisinopril—systemic scleroderma	0.000188	0.000684	CcSEcCtD
Naltrexone—Vomiting—Captopril—systemic scleroderma	0.000188	0.000684	CcSEcCtD
Naltrexone—Dry mouth—Mycophenolate mofetil—systemic scleroderma	0.000187	0.000681	CcSEcCtD
Naltrexone—Dyspnoea—Lisinopril—systemic scleroderma	0.000187	0.00068	CcSEcCtD
Naltrexone—Rash—Captopril—systemic scleroderma	0.000186	0.000679	CcSEcCtD
Naltrexone—Dermatitis—Captopril—systemic scleroderma	0.000186	0.000678	CcSEcCtD
Naltrexone—Somnolence—Lisinopril—systemic scleroderma	0.000186	0.000678	CcSEcCtD
Naltrexone—Headache—Captopril—systemic scleroderma	0.000185	0.000674	CcSEcCtD
Naltrexone—Confusional state—Mycophenolate mofetil—systemic scleroderma	0.000185	0.000673	CcSEcCtD
Naltrexone—Body temperature increased—Mycophenolic acid—systemic scleroderma	0.000184	0.000669	CcSEcCtD
Naltrexone—Abdominal pain—Mycophenolic acid—systemic scleroderma	0.000184	0.000669	CcSEcCtD
Naltrexone—Anaphylactic shock—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000668	CcSEcCtD
Naltrexone—Oedema—Mycophenolate mofetil—systemic scleroderma	0.000183	0.000668	CcSEcCtD
Naltrexone—Infection—Mycophenolate mofetil—systemic scleroderma	0.000182	0.000663	CcSEcCtD
Naltrexone—Decreased appetite—Lisinopril—systemic scleroderma	0.000182	0.000663	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Lisinopril—systemic scleroderma	0.000181	0.000658	CcSEcCtD
Naltrexone—Fatigue—Lisinopril—systemic scleroderma	0.00018	0.000657	CcSEcCtD
Naltrexone—Shock—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000657	CcSEcCtD
Naltrexone—Nervous system disorder—Mycophenolate mofetil—systemic scleroderma	0.00018	0.000655	CcSEcCtD
Naltrexone—Hypersensitivity—Leflunomide—systemic scleroderma	0.000179	0.000654	CcSEcCtD
Naltrexone—Pain—Lisinopril—systemic scleroderma	0.000179	0.000652	CcSEcCtD
Naltrexone—Constipation—Lisinopril—systemic scleroderma	0.000179	0.000652	CcSEcCtD
Naltrexone—Tachycardia—Mycophenolate mofetil—systemic scleroderma	0.000179	0.000652	CcSEcCtD
Naltrexone—Skin disorder—Mycophenolate mofetil—systemic scleroderma	0.000178	0.000649	CcSEcCtD
Naltrexone—Hyperhidrosis—Mycophenolate mofetil—systemic scleroderma	0.000177	0.000646	CcSEcCtD
Naltrexone—Diarrhoea—Azathioprine—systemic scleroderma	0.000176	0.000643	CcSEcCtD
Naltrexone—Nausea—Captopril—systemic scleroderma	0.000176	0.000639	CcSEcCtD
Naltrexone—Abdominal discomfort—Methotrexate—systemic scleroderma	0.000175	0.000638	CcSEcCtD
Naltrexone—Anorexia—Mycophenolate mofetil—systemic scleroderma	0.000175	0.000637	CcSEcCtD
Naltrexone—Asthenia—Leflunomide—systemic scleroderma	0.000175	0.000636	CcSEcCtD
Naltrexone—Hallucination—Prednisone—systemic scleroderma	0.000174	0.000634	CcSEcCtD
Naltrexone—Feeling abnormal—Lisinopril—systemic scleroderma	0.000172	0.000628	CcSEcCtD
Naltrexone—Pruritus—Leflunomide—systemic scleroderma	0.000172	0.000628	CcSEcCtD
Naltrexone—Connective tissue disorder—Prednisone—systemic scleroderma	0.000172	0.000626	CcSEcCtD
Naltrexone—Gastrointestinal pain—Lisinopril—systemic scleroderma	0.000171	0.000623	CcSEcCtD
Naltrexone—Dizziness—Azathioprine—systemic scleroderma	0.000171	0.000621	CcSEcCtD
Naltrexone—Upper respiratory tract infection—Methotrexate—systemic scleroderma	0.00017	0.000618	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Mycophenolate mofetil—systemic scleroderma	0.000167	0.000608	CcSEcCtD
Naltrexone—Asthenia—Mycophenolic acid—systemic scleroderma	0.000167	0.000607	CcSEcCtD
Naltrexone—Diarrhoea—Leflunomide—systemic scleroderma	0.000167	0.000607	CcSEcCtD
Naltrexone—Urticaria—Lisinopril—systemic scleroderma	0.000166	0.000606	CcSEcCtD
Naltrexone—Insomnia—Mycophenolate mofetil—systemic scleroderma	0.000166	0.000604	CcSEcCtD
Naltrexone—Body temperature increased—Lisinopril—systemic scleroderma	0.000165	0.000603	CcSEcCtD
Naltrexone—Abdominal pain—Lisinopril—systemic scleroderma	0.000165	0.000603	CcSEcCtD
Naltrexone—Paraesthesia—Mycophenolate mofetil—systemic scleroderma	0.000165	0.0006	CcSEcCtD
Naltrexone—Pruritus—Mycophenolic acid—systemic scleroderma	0.000164	0.000599	CcSEcCtD
Naltrexone—Vomiting—Azathioprine—systemic scleroderma	0.000164	0.000597	CcSEcCtD
Naltrexone—Pneumonia—Methotrexate—systemic scleroderma	0.000164	0.000597	CcSEcCtD
Naltrexone—Eye disorder—Prednisone—systemic scleroderma	0.000164	0.000595	CcSEcCtD
Naltrexone—Dyspnoea—Mycophenolate mofetil—systemic scleroderma	0.000164	0.000595	CcSEcCtD
Naltrexone—Somnolence—Mycophenolate mofetil—systemic scleroderma	0.000163	0.000594	CcSEcCtD
Naltrexone—Infestation NOS—Methotrexate—systemic scleroderma	0.000163	0.000593	CcSEcCtD
Naltrexone—Infestation—Methotrexate—systemic scleroderma	0.000163	0.000593	CcSEcCtD
Naltrexone—Rash—Azathioprine—systemic scleroderma	0.000163	0.000592	CcSEcCtD
Naltrexone—Dermatitis—Azathioprine—systemic scleroderma	0.000162	0.000592	CcSEcCtD
Naltrexone—Depression—Methotrexate—systemic scleroderma	0.000162	0.000591	CcSEcCtD
Naltrexone—Headache—Azathioprine—systemic scleroderma	0.000162	0.000588	CcSEcCtD
Naltrexone—Dizziness—Leflunomide—systemic scleroderma	0.000161	0.000587	CcSEcCtD
Naltrexone—Decreased appetite—Mycophenolate mofetil—systemic scleroderma	0.000159	0.000581	CcSEcCtD
Naltrexone—Diarrhoea—Mycophenolic acid—systemic scleroderma	0.000159	0.000579	CcSEcCtD
Naltrexone—Angiopathy—Prednisone—systemic scleroderma	0.000159	0.000578	CcSEcCtD
Naltrexone—Conjunctivitis—Methotrexate—systemic scleroderma	0.000158	0.000577	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Mycophenolate mofetil—systemic scleroderma	0.000158	0.000577	CcSEcCtD
Naltrexone—Immune system disorder—Prednisone—systemic scleroderma	0.000158	0.000576	CcSEcCtD
Naltrexone—Constipation—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000571	CcSEcCtD
Naltrexone—Pain—Mycophenolate mofetil—systemic scleroderma	0.000157	0.000571	CcSEcCtD
Naltrexone—Vomiting—Leflunomide—systemic scleroderma	0.000155	0.000564	CcSEcCtD
Naltrexone—Alopecia—Prednisone—systemic scleroderma	0.000155	0.000563	CcSEcCtD
Naltrexone—Hypersensitivity—Lisinopril—systemic scleroderma	0.000154	0.000562	CcSEcCtD
Naltrexone—Hepatobiliary disease—Methotrexate—systemic scleroderma	0.000154	0.000561	CcSEcCtD
Naltrexone—Dizziness—Mycophenolic acid—systemic scleroderma	0.000154	0.00056	CcSEcCtD
Naltrexone—Epistaxis—Methotrexate—systemic scleroderma	0.000154	0.00056	CcSEcCtD
Naltrexone—Rash—Leflunomide—systemic scleroderma	0.000154	0.000559	CcSEcCtD
Naltrexone—Dermatitis—Leflunomide—systemic scleroderma	0.000153	0.000559	CcSEcCtD
Naltrexone—Mental disorder—Prednisone—systemic scleroderma	0.000153	0.000558	CcSEcCtD
Naltrexone—Nausea—Azathioprine—systemic scleroderma	0.000153	0.000558	CcSEcCtD
Naltrexone—Headache—Leflunomide—systemic scleroderma	0.000153	0.000556	CcSEcCtD
Naltrexone—Malnutrition—Prednisone—systemic scleroderma	0.000152	0.000555	CcSEcCtD
Naltrexone—Feeling abnormal—Mycophenolate mofetil—systemic scleroderma	0.000151	0.00055	CcSEcCtD
Naltrexone—Asthenia—Lisinopril—systemic scleroderma	0.00015	0.000547	CcSEcCtD
Naltrexone—Gastrointestinal pain—Mycophenolate mofetil—systemic scleroderma	0.00015	0.000546	CcSEcCtD
Naltrexone—Pruritus—Lisinopril—systemic scleroderma	0.000148	0.000539	CcSEcCtD
Naltrexone—Vomiting—Mycophenolic acid—systemic scleroderma	0.000148	0.000538	CcSEcCtD
Naltrexone—Rash—Mycophenolic acid—systemic scleroderma	0.000147	0.000534	CcSEcCtD
Naltrexone—Dermatitis—Mycophenolic acid—systemic scleroderma	0.000146	0.000533	CcSEcCtD
Naltrexone—Hepatitis—Methotrexate—systemic scleroderma	0.000146	0.000533	CcSEcCtD
Naltrexone—Urticaria—Mycophenolate mofetil—systemic scleroderma	0.000146	0.000531	CcSEcCtD
Naltrexone—Headache—Mycophenolic acid—systemic scleroderma	0.000146	0.00053	CcSEcCtD
Naltrexone—Pharyngitis—Methotrexate—systemic scleroderma	0.000145	0.000529	CcSEcCtD
Naltrexone—Abdominal pain—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000528	CcSEcCtD
Naltrexone—Body temperature increased—Mycophenolate mofetil—systemic scleroderma	0.000145	0.000528	CcSEcCtD
Naltrexone—Nausea—Leflunomide—systemic scleroderma	0.000145	0.000527	CcSEcCtD
Naltrexone—Vision blurred—Prednisone—systemic scleroderma	0.000144	0.000523	CcSEcCtD
Naltrexone—Diarrhoea—Lisinopril—systemic scleroderma	0.000143	0.000522	CcSEcCtD
Naltrexone—Ill-defined disorder—Prednisone—systemic scleroderma	0.000141	0.000515	CcSEcCtD
Naltrexone—Agitation—Prednisone—systemic scleroderma	0.00014	0.00051	CcSEcCtD
Naltrexone—Angioedema—Prednisone—systemic scleroderma	0.000139	0.000507	CcSEcCtD
Naltrexone—Dizziness—Lisinopril—systemic scleroderma	0.000138	0.000504	CcSEcCtD
Naltrexone—Nausea—Mycophenolic acid—systemic scleroderma	0.000138	0.000503	CcSEcCtD
Naltrexone—Malaise—Prednisone—systemic scleroderma	0.000137	0.0005	CcSEcCtD
Naltrexone—Eye disorder—Methotrexate—systemic scleroderma	0.000137	0.000498	CcSEcCtD
Naltrexone—Syncope—Prednisone—systemic scleroderma	0.000137	0.000497	CcSEcCtD
Naltrexone—Tinnitus—Methotrexate—systemic scleroderma	0.000136	0.000497	CcSEcCtD
Naltrexone—Cardiac disorder—Methotrexate—systemic scleroderma	0.000136	0.000494	CcSEcCtD
Naltrexone—Hypersensitivity—Mycophenolate mofetil—systemic scleroderma	0.000135	0.000492	CcSEcCtD
Naltrexone—Loss of consciousness—Prednisone—systemic scleroderma	0.000134	0.000488	CcSEcCtD
Naltrexone—Vomiting—Lisinopril—systemic scleroderma	0.000133	0.000485	CcSEcCtD
Naltrexone—Angiopathy—Methotrexate—systemic scleroderma	0.000133	0.000483	CcSEcCtD
Naltrexone—Immune system disorder—Methotrexate—systemic scleroderma	0.000132	0.000481	CcSEcCtD
Naltrexone—Rash—Lisinopril—systemic scleroderma	0.000132	0.000481	CcSEcCtD
Naltrexone—Convulsion—Prednisone—systemic scleroderma	0.000132	0.000481	CcSEcCtD
Naltrexone—Dermatitis—Lisinopril—systemic scleroderma	0.000132	0.00048	CcSEcCtD
Naltrexone—Mediastinal disorder—Methotrexate—systemic scleroderma	0.000132	0.00048	CcSEcCtD
Naltrexone—Asthenia—Mycophenolate mofetil—systemic scleroderma	0.000132	0.000479	CcSEcCtD
Naltrexone—Hypertension—Prednisone—systemic scleroderma	0.000132	0.000479	CcSEcCtD
Naltrexone—Chills—Methotrexate—systemic scleroderma	0.000131	0.000478	CcSEcCtD
Naltrexone—Headache—Lisinopril—systemic scleroderma	0.000131	0.000478	CcSEcCtD
Naltrexone—Pruritus—Mycophenolate mofetil—systemic scleroderma	0.00013	0.000472	CcSEcCtD
Naltrexone—Myalgia—Prednisone—systemic scleroderma	0.00013	0.000472	CcSEcCtD
Naltrexone—Arthralgia—Prednisone—systemic scleroderma	0.00013	0.000472	CcSEcCtD
Naltrexone—Anxiety—Prednisone—systemic scleroderma	0.000129	0.000471	CcSEcCtD
Naltrexone—Alopecia—Methotrexate—systemic scleroderma	0.000129	0.000471	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Prednisone—systemic scleroderma	0.000129	0.000469	CcSEcCtD
Naltrexone—Discomfort—Prednisone—systemic scleroderma	0.000128	0.000467	CcSEcCtD
Naltrexone—Mental disorder—Methotrexate—systemic scleroderma	0.000128	0.000467	CcSEcCtD
Naltrexone—Malnutrition—Methotrexate—systemic scleroderma	0.000127	0.000464	CcSEcCtD
Naltrexone—Diarrhoea—Mycophenolate mofetil—systemic scleroderma	0.000125	0.000457	CcSEcCtD
Naltrexone—Dysgeusia—Methotrexate—systemic scleroderma	0.000125	0.000454	CcSEcCtD
Naltrexone—Nausea—Lisinopril—systemic scleroderma	0.000124	0.000453	CcSEcCtD
Naltrexone—Anaphylactic shock—Prednisone—systemic scleroderma	0.000124	0.000453	CcSEcCtD
Naltrexone—Oedema—Prednisone—systemic scleroderma	0.000124	0.000453	CcSEcCtD
Naltrexone—Infection—Prednisone—systemic scleroderma	0.000124	0.00045	CcSEcCtD
Naltrexone—Back pain—Methotrexate—systemic scleroderma	0.000123	0.000448	CcSEcCtD
Naltrexone—Shock—Prednisone—systemic scleroderma	0.000122	0.000445	CcSEcCtD
Naltrexone—Nervous system disorder—Prednisone—systemic scleroderma	0.000122	0.000444	CcSEcCtD
Naltrexone—Tachycardia—Prednisone—systemic scleroderma	0.000121	0.000442	CcSEcCtD
Naltrexone—Dizziness—Mycophenolate mofetil—systemic scleroderma	0.000121	0.000442	CcSEcCtD
Naltrexone—Skin disorder—Prednisone—systemic scleroderma	0.000121	0.00044	CcSEcCtD
Naltrexone—Hyperhidrosis—Prednisone—systemic scleroderma	0.00012	0.000438	CcSEcCtD
Naltrexone—Vision blurred—Methotrexate—systemic scleroderma	0.00012	0.000437	CcSEcCtD
Naltrexone—Anorexia—Prednisone—systemic scleroderma	0.000118	0.000432	CcSEcCtD
Naltrexone—Ill-defined disorder—Methotrexate—systemic scleroderma	0.000118	0.00043	CcSEcCtD
Naltrexone—Vomiting—Mycophenolate mofetil—systemic scleroderma	0.000117	0.000425	CcSEcCtD
Naltrexone—Rash—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000421	CcSEcCtD
Naltrexone—Dermatitis—Mycophenolate mofetil—systemic scleroderma	0.000116	0.000421	CcSEcCtD
Naltrexone—Headache—Mycophenolate mofetil—systemic scleroderma	0.000115	0.000418	CcSEcCtD
Naltrexone—Malaise—Methotrexate—systemic scleroderma	0.000115	0.000418	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Prednisone—systemic scleroderma	0.000113	0.000412	CcSEcCtD
Naltrexone—Insomnia—Prednisone—systemic scleroderma	0.000112	0.000409	CcSEcCtD
Naltrexone—Paraesthesia—Prednisone—systemic scleroderma	0.000112	0.000406	CcSEcCtD
Naltrexone—Cough—Methotrexate—systemic scleroderma	0.000111	0.000405	CcSEcCtD
Naltrexone—Convulsion—Methotrexate—systemic scleroderma	0.00011	0.000402	CcSEcCtD
Naltrexone—Nausea—Mycophenolate mofetil—systemic scleroderma	0.000109	0.000397	CcSEcCtD
Naltrexone—Chest pain—Methotrexate—systemic scleroderma	0.000108	0.000395	CcSEcCtD
Naltrexone—Myalgia—Methotrexate—systemic scleroderma	0.000108	0.000395	CcSEcCtD
Naltrexone—Arthralgia—Methotrexate—systemic scleroderma	0.000108	0.000395	CcSEcCtD
Naltrexone—Decreased appetite—Prednisone—systemic scleroderma	0.000108	0.000394	CcSEcCtD
Naltrexone—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—systemic scleroderma	0.000108	0.000392	CcSEcCtD
Naltrexone—Fatigue—Prednisone—systemic scleroderma	0.000107	0.00039	CcSEcCtD
Naltrexone—Discomfort—Methotrexate—systemic scleroderma	0.000107	0.00039	CcSEcCtD
Naltrexone—Constipation—Prednisone—systemic scleroderma	0.000106	0.000387	CcSEcCtD
Naltrexone—Confusional state—Methotrexate—systemic scleroderma	0.000105	0.000381	CcSEcCtD
Naltrexone—Anaphylactic shock—Methotrexate—systemic scleroderma	0.000104	0.000378	CcSEcCtD
Naltrexone—Infection—Methotrexate—systemic scleroderma	0.000103	0.000376	CcSEcCtD
Naltrexone—Feeling abnormal—Prednisone—systemic scleroderma	0.000102	0.000373	CcSEcCtD
Naltrexone—Nervous system disorder—Methotrexate—systemic scleroderma	0.000102	0.000371	CcSEcCtD
Naltrexone—Gastrointestinal pain—Prednisone—systemic scleroderma	0.000102	0.00037	CcSEcCtD
Naltrexone—Skin disorder—Methotrexate—systemic scleroderma	0.000101	0.000367	CcSEcCtD
Naltrexone—Hyperhidrosis—Methotrexate—systemic scleroderma	0.0001	0.000366	CcSEcCtD
Naltrexone—Anorexia—Methotrexate—systemic scleroderma	9.9e-05	0.000361	CcSEcCtD
Naltrexone—Urticaria—Prednisone—systemic scleroderma	9.88e-05	0.00036	CcSEcCtD
Naltrexone—Body temperature increased—Prednisone—systemic scleroderma	9.83e-05	0.000358	CcSEcCtD
Naltrexone—Abdominal pain—Prednisone—systemic scleroderma	9.83e-05	0.000358	CcSEcCtD
Naltrexone—Musculoskeletal discomfort—Methotrexate—systemic scleroderma	9.47e-05	0.000345	CcSEcCtD
Naltrexone—Insomnia—Methotrexate—systemic scleroderma	9.4e-05	0.000342	CcSEcCtD
Naltrexone—Paraesthesia—Methotrexate—systemic scleroderma	9.33e-05	0.00034	CcSEcCtD
Naltrexone—Dyspnoea—Methotrexate—systemic scleroderma	9.26e-05	0.000337	CcSEcCtD
Naltrexone—Somnolence—Methotrexate—systemic scleroderma	9.24e-05	0.000336	CcSEcCtD
Naltrexone—Hypersensitivity—Prednisone—systemic scleroderma	9.16e-05	0.000334	CcSEcCtD
Naltrexone—Decreased appetite—Methotrexate—systemic scleroderma	9.03e-05	0.000329	CcSEcCtD
Naltrexone—Gastrointestinal disorder—Methotrexate—systemic scleroderma	8.97e-05	0.000327	CcSEcCtD
Naltrexone—Fatigue—Methotrexate—systemic scleroderma	8.96e-05	0.000326	CcSEcCtD
Naltrexone—Asthenia—Prednisone—systemic scleroderma	8.92e-05	0.000325	CcSEcCtD
Naltrexone—Pain—Methotrexate—systemic scleroderma	8.88e-05	0.000324	CcSEcCtD
Naltrexone—Pruritus—Prednisone—systemic scleroderma	8.8e-05	0.00032	CcSEcCtD
Naltrexone—Feeling abnormal—Methotrexate—systemic scleroderma	8.56e-05	0.000312	CcSEcCtD
Naltrexone—Diarrhoea—Prednisone—systemic scleroderma	8.51e-05	0.00031	CcSEcCtD
Naltrexone—Gastrointestinal pain—Methotrexate—systemic scleroderma	8.5e-05	0.000309	CcSEcCtD
Naltrexone—Urticaria—Methotrexate—systemic scleroderma	8.25e-05	0.000301	CcSEcCtD
Naltrexone—Dizziness—Prednisone—systemic scleroderma	8.22e-05	0.000299	CcSEcCtD
Naltrexone—Abdominal pain—Methotrexate—systemic scleroderma	8.21e-05	0.000299	CcSEcCtD
Naltrexone—Body temperature increased—Methotrexate—systemic scleroderma	8.21e-05	0.000299	CcSEcCtD
Naltrexone—Vomiting—Prednisone—systemic scleroderma	7.9e-05	0.000288	CcSEcCtD
Naltrexone—Rash—Prednisone—systemic scleroderma	7.84e-05	0.000285	CcSEcCtD
Naltrexone—Dermatitis—Prednisone—systemic scleroderma	7.83e-05	0.000285	CcSEcCtD
Naltrexone—Headache—Prednisone—systemic scleroderma	7.79e-05	0.000284	CcSEcCtD
Naltrexone—Hypersensitivity—Methotrexate—systemic scleroderma	7.65e-05	0.000279	CcSEcCtD
Naltrexone—Asthenia—Methotrexate—systemic scleroderma	7.45e-05	0.000271	CcSEcCtD
Naltrexone—Nausea—Prednisone—systemic scleroderma	7.38e-05	0.000269	CcSEcCtD
Naltrexone—Pruritus—Methotrexate—systemic scleroderma	7.35e-05	0.000268	CcSEcCtD
Naltrexone—Diarrhoea—Methotrexate—systemic scleroderma	7.11e-05	0.000259	CcSEcCtD
Naltrexone—Dizziness—Methotrexate—systemic scleroderma	6.87e-05	0.00025	CcSEcCtD
Naltrexone—Vomiting—Methotrexate—systemic scleroderma	6.61e-05	0.000241	CcSEcCtD
Naltrexone—Rash—Methotrexate—systemic scleroderma	6.55e-05	0.000239	CcSEcCtD
Naltrexone—Dermatitis—Methotrexate—systemic scleroderma	6.54e-05	0.000238	CcSEcCtD
Naltrexone—Headache—Methotrexate—systemic scleroderma	6.51e-05	0.000237	CcSEcCtD
Naltrexone—Nausea—Methotrexate—systemic scleroderma	6.17e-05	0.000225	CcSEcCtD
